Taken together, we initially hypothesized that clinically meaningful and statistically significant cancer control differences may occur in mCRPC men pretreated with radium- 223 and subsequent Lu- 177-PSMA therapy, relative to radium- 223-naïve Lu- 177-PSMA mCRPC patients. Here, FOLH1 is linked to cancer.